6-Thioguanine Rectal Suppository Composition for Low Liver Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Oral administration of 6-thioguanine is associated with high liver toxicity and requires careful monitoring, especially in patients with thiopurine methyltransferase or Nudix hydrolase 15 deficiencies, and existing rectal formulations lack standardized excipients and efficient drug delivery.
Innovation Solution
A rectal suppository comprising 6-thioguanine, hard fat, and surfactant, with controlled particle size and specific excipient ratios, providing controlled drug release and reduced systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral formulations of 6-thioguanine are used to treat inflammatory bowel disease, then systemic therapeutic effect is achieved, but liver toxicity and systemic side effects increase
Solution Approach 1:
The invention divides the administration route into localized rectal delivery rather than systemic oral delivery. The suppository formulation segments the drug delivery system to target specifically the distal bowel, preventing systemic circulation and liver exposure while maintaining therapeutic efficacy at the disease site.
Solution Approach 2:
The rectal suppository provides localized high concentration of 6-thioguanine at the rectal and distal colonic mucosa where inflammatory bowel disease affects the distal bowel. This local quality ensures high therapeutic effect at the target site while minimizing systemic absorption and liver toxicity.
2Reliability
If high dose 6-thioguanine is administered to achieve therapeutic effect, then disease control improves, but risk of toxicity increases
Solution Approach 1:
The rectal suppository creates a local high-concentration reservoir of 6-thioguanine at the distal bowel mucosa, achieving effective local dosing without proportionally increasing systemic exposure. The localized formulation allows high local drug concentration while limiting systemic toxicity.
Solution Approach 2:
The rectal mucosa acts as an intermediary that absorbs the drug locally for direct therapeutic effect on the inflamed distal bowel. This intermediary approach bypasses first-pass hepatic metabolism and systemic circulation, reducing toxicity while maintaining disease control.
3Duration of action of stationary object
If oral 6-thioguanine is used for long-term maintenance therapy, then sustained therapeutic effect is achieved, but cumulative liver toxicity occurs
Solution Approach 1:
The rectal suppository enables long-term maintenance therapy by segmenting the delivery system to avoid hepatic exposure. Each suppository provides sustained local release of 6-thioguanine at the distal bowel, allowing prolonged treatment without cumulative liver toxicity associated with oral formulations.
Solution Approach 2:
The rectal suppository formulation provides continuous localized therapeutic action at the distal bowel site over extended periods. The sustained release from the suppository matrix maintains effective local drug concentrations for maintenance therapy without the cumulative hepatotoxicity of continuous oral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The suppository achieves effective local drug delivery with minimal systemic absorption, reducing liver toxicity risks and improving treatment efficacy for inflammatory bowel diseases.
Implementation Method 1
at least one surfactant
Implementation Method 2
at least one hard fat
Data Source
AI summary
Described is a rectal suppository. The rectal suppository comprises 6-thioguanine, at least one hard fat, and at least one surfactant. Further or alternatively, the rectal suppository comprises about 1 to 9 mg of 6-thioguanine. Further or alternatively, there is described a method of preventing, treating and/or managing inflammatory bowel disease in a subject. The method comprises administering a rectal suppository to the subject in need thereof. Further or alternatively, there is described a method of manufacturing a rectal suppository. The method comprises the steps of (a) heating a hard fat to become a liquid hard fat, (b) adding at least one surfactant to the liquid hard fat, (c) adding 6-thioguanine to the liquid hard fat, (d) forming the hard fat into a rectal suppository. Step (b) is optionally carried out before step (c) or after step (c).